tradingview.comNov 10$MANE

Veradermics Reports Q3 2026 Results, $798.4 Million in Cash and Positive Trial Data

Veradermics reported a Q3 2026 net loss of $21.0M, up from $20.1M a year earlier, with $798.4M in cash. Positive trial data for VDPHL01 in hair loss was highlighted. R&D expenses decreased to $16.1M, while operating expenses rose to $28.8M. The company expects topline results from Study 306 in H1 2027.

Original reporting

tradingview.com

Published Nov 10, 2026, 2:03 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 2:10 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Veradermics Reports Q3 2026 Results, $798.4 Million in Cash and Positive Trial Data — source image — Source · tradingview.com

Decision brief

The 30-second read

$MANEBullishMed

Why it matters

The cash buildup and trial readouts improve the company's financial stability and de‑risk its pipeline, likely supporting a price rally.

Market read

The disclosure provides fresh, material information that can move the stock and influences the biotech sector.

What to watch

Potential competition from other hair‑loss therapies and need for Phase 3 confirmatory data.

Relevance 9/10Novelty 9/10Timing: post‑market today

Background

Veradermics Inc (MANE) filed an 8‑K reporting Q3 2026 financials and positive clinical results for its hair‑loss candidate VDPHL01.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MANEBullishHigh confidence

Context

Q3 2026 results showing $798.4M cash and positive Phase 2/3 hair loss trial data for VDPHL01.

Expected impact

likely upward pressure as investors price in successful trial outcomes.

Evidence & confidence

Biotech trials are material catalysts; cash runway reduces near‑term financing risk.

Market effects

Sector

Positive hair‑loss trial data may lift peer biotech stocks in dermatology and hair‑loss space.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Modest; primarily relevant to investors tracking US‑listed biotech pipelines.

Counterpoint

What could challenge this read

Trial success does not guarantee commercial approval; regulatory risk remains.

Key entities

company
Veradermics Inc
US‑listed biotech developing VDPHL01 for hair loss.

Read at source ← All news

$MANEMed

MANE Q3 net loss $21.0M vs $20.1M y/y; cash $798.4M funds ops into 2030; Phase 3 302 and 304 data positive

Veradermics reported a Q3 2026 net loss of $21.0M, slightly higher than the $20.1M loss in Q3 2025. The company has $798.4M in cash, expected to fund operations into 2030. Positive Phase 3 data for VDPHL01 was reported, with a Phase 2/3 readout expected in early 2027. R&D expenses decreased, but G&A expenses rose year over year.

quantisnow.comNov 10

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

SEC EDGAR 8-KNov 10

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

investing.comNov 9

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

investing.comNov 9

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.

tradingview.comNov 9